Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

This study is testing a combination of chemotherapy drugs — cytarabine and venetoclax — as a consolidation treatment for older adults with acute myeloid leukemia (AML) who have already responded to initial treatment. **You may be eligible if...** - You are between 60 and 75 years old - You have been diagnosed with AML (a type of blood cancer) and achieved remission after initial chemotherapy - Your cancer is classified as intermediate or high risk - You are not a candidate for a bone marrow transplant - You have adequate liver, kidney, and heart function **You may NOT be eligible if...** - You are allergic to any of the drugs in the trial - Your leukemia has relapsed (more than 5% cancer cells in bone marrow) - You have another active cancer requiring treatment - You have severe liver, kidney, or heart problems - You have a history of drug or alcohol dependence Talk to your doctor to see if this trial is right for you.